Glycominds
Glycominds is a leading microbiome biomarker research company specializing in non-invasive diagnostics for gastrointestinal diseases, including Inflammatory Bowel Disease (IBD). They develop and commercialize serum biomarker tests and kits to provide accurate, cost-effective diagnosis, prognosis, and therapy monitoring, aiming to improve patient care through innovative, validated technology platforms.
Industries
Nr. of Employees
small (1-50)
Products
CE-marked serological IBD diagnostic panel (IBDX antibody panel)
A series of CE-marked in vitro diagnostic kits composed of multiple serological antibodies intended to assist differential diagnosis between Crohn's disease and ulcerative colitis and to provide prognostic information about Crohn's disease progression.
Ulcerative Colitis Response Index (UCRI) — multi-immune biomarker test
A multi-analyte composite index based on analysis of multiple innate-immunity and inflammatory biomarkers designed as a surrogate marker for endoscopic response and early detection of mucosal healing in ulcerative colitis patients.
Dried-specimen collection and shipping solution
A dry blood/serum specimen collection and shipping workflow intended to reduce specimen transport costs and enable remote/home sampling for laboratory testing.
CE-marked serological IBD diagnostic panel (IBDX antibody panel)
A series of CE-marked in vitro diagnostic kits composed of multiple serological antibodies intended to assist differential diagnosis between Crohn's disease and ulcerative colitis and to provide prognostic information about Crohn's disease progression.
Ulcerative Colitis Response Index (UCRI) — multi-immune biomarker test
A multi-analyte composite index based on analysis of multiple innate-immunity and inflammatory biomarkers designed as a surrogate marker for endoscopic response and early detection of mucosal healing in ulcerative colitis patients.
Dried-specimen collection and shipping solution
A dry blood/serum specimen collection and shipping workflow intended to reduce specimen transport costs and enable remote/home sampling for laboratory testing.
Services
Assistance for organizations to become regional distributors and to offer diagnostic kits in additional countries.
Assistance for organizations to become regional distributors and to offer diagnostic kits in additional countries.
Expertise Areas
- Microbiome biomarker research
- Serological assay development and validation
- In vitro diagnostic (IVD) kit development
- Clinical trial design and multicenter validation
Key Technologies
- Serological antibody panels
- Multi-analyte composite biomarker indices
- Dried blood/serum specimen collection
- CE-marked IVD kit formats
News & Updates
Presentation of the UCRI study at IBD Innovate for Crohn’s & Colitis™.
Lyfebulb announces finalists for the 2022 Innovation Challenge addressing unmet needs in IBD.
Introduction of finalists for the 2021 Lyfebulb and Arena IBD pharmaceuticals innovation.
Discussion on diagnostics at IBD Ventures.
Achieved CE MARK regulation, enabling global distribution of IBD diagnostic kits.
Presentation of the UCRI study at IBD Innovate for Crohn’s & Colitis™.
Lyfebulb announces finalists for the 2022 Innovation Challenge addressing unmet needs in IBD.
Introduction of finalists for the 2021 Lyfebulb and Arena IBD pharmaceuticals innovation.
Discussion on diagnostics at IBD Ventures.
Achieved CE MARK regulation, enabling global distribution of IBD diagnostic kits.